93 related articles for article (PubMed ID: 28346289)
1. β-Blocker use and reduced disease progression in patients with thick melanoma: 8 years of follow-up.
De Giorgi V; Grazzini M; Benemei S; Marchionni N; Geppetti P; Gandini S
Melanoma Res; 2017 Jun; 27(3):268-270. PubMed ID: 28346289
[TBL] [Abstract][Full Text] [Related]
2. Treatment with β-blockers and reduced disease progression in patients with thick melanoma.
De Giorgi V; Grazzini M; Gandini S; Benemei S; Lotti T; Marchionni N; Geppetti P
Arch Intern Med; 2011 Apr; 171(8):779-81. PubMed ID: 21518948
[TBL] [Abstract][Full Text] [Related]
3. β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study.
Lemeshow S; Sørensen HT; Phillips G; Yang EV; Antonsen S; Riis AH; Lesinski GB; Jackson R; Glaser R
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2273-9. PubMed ID: 21933972
[TBL] [Abstract][Full Text] [Related]
4. Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death.
De Giorgi V; Gandini S; Grazzini M; Benemei S; Marchionni N; Geppetti P
Mayo Clin Proc; 2013 Nov; 88(11):1196-203. PubMed ID: 24182700
[TBL] [Abstract][Full Text] [Related]
5. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study.
Livingstone E; Hollestein LM; van Herk-Sukel MP; van de Poll-Franse L; Nijsten T; Schadendorf D; de Vries E
Eur J Cancer; 2013 Dec; 49(18):3863-71. PubMed ID: 23942335
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma.
Parker WP; Lohse CM; Zaid HB; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
Urol Oncol; 2017 Jan; 35(1):36.e1-36.e6. PubMed ID: 27687543
[TBL] [Abstract][Full Text] [Related]
7. Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study.
De Giorgi V; Grazzini M; Benemei S; Marchionni N; Botteri E; Pennacchioli E; Geppetti P; Gandini S
JAMA Oncol; 2018 Feb; 4(2):e172908. PubMed ID: 28973254
[TBL] [Abstract][Full Text] [Related]
8. Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study.
McCourt C; Coleman HG; Murray LJ; Cantwell MM; Dolan O; Powe DG; Cardwell CR
Br J Dermatol; 2014 Apr; 170(4):930-8. PubMed ID: 24593055
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
[TBL] [Abstract][Full Text] [Related]
10. Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study.
Gu J; Fan YQ; Bian L; Zhang HL; Xu ZJ; Zhang Y; Chen QZ; Yin ZF; Xie YS; Wang CQ
Eur J Prev Cardiol; 2016 Sep; 23(13):1421-8. PubMed ID: 26915580
[TBL] [Abstract][Full Text] [Related]
11. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
[TBL] [Abstract][Full Text] [Related]
12. Stage-specific associations between beta blocker use and prognosis after colorectal cancer.
Jansen L; Hoffmeister M; Arndt V; Chang-Claude J; Brenner H
Cancer; 2014 Apr; 120(8):1178-86. PubMed ID: 24415516
[TBL] [Abstract][Full Text] [Related]
13. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA
Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
[TBL] [Abstract][Full Text] [Related]
14. β-adrenergic-blocking drugs and melanoma: current state of the art.
De Giorgi V; Grazzini M; Gandini S; Benemei S; Asbury CD; Marchionni N; Geppetti P
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1461-7. PubMed ID: 23249110
[TBL] [Abstract][Full Text] [Related]
15. Ultrasound-based follow-up does not increase survival in early-stage melanoma patients: A comparative cohort study.
Ribero S; Podlipnik S; Osella-Abate S; Sportoletti-Baduel E; Manubens E; Barreiro A; Caliendo V; Chavez-Bourgeois M; Carrera C; Cassoni P; Malvehy J; Fierro MT; Puig S
Eur J Cancer; 2017 Nov; 85():59-66. PubMed ID: 28888850
[TBL] [Abstract][Full Text] [Related]
16. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.
Lanfear DE; Jones PG; Marsh S; Cresci S; McLeod HL; Spertus JA
JAMA; 2005 Sep; 294(12):1526-33. PubMed ID: 16189366
[TBL] [Abstract][Full Text] [Related]
17. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
[TBL] [Abstract][Full Text] [Related]
18. [β-blockers: a new and emerging treatment for melanoma].
De Giorgi V; Gandini S; Grazzini M; Benemei S; Marchionni N; Geppetti P
Recenti Prog Med; 2012 Jan; 103(1):11-6. PubMed ID: 22322621
[TBL] [Abstract][Full Text] [Related]
19. Postdiagnostic use of β-blockers and other antihypertensive drugs and the risk of recurrence and mortality in head and neck cancer patients: an observational study of 10,414 person-years of follow-up.
Kim SA; Moon H; Roh JL; Kim SB; Choi SH; Nam SY; Kim SY
Clin Transl Oncol; 2017 Jul; 19(7):826-833. PubMed ID: 28093700
[TBL] [Abstract][Full Text] [Related]
20. Comparison of late mortality in hospitalized patients >70 years of age with systolic heart failure receiving beta blockers versus those not receiving beta blockers.
Pascual-Figal DA; Redondo B; Caro C; Manzano S; Garrido IP; Ruipérez JA; Valdés M
Am J Cardiol; 2008 Dec; 102(12):1711-7. PubMed ID: 19064029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
